ZURA
HealthcareZura Bio Limited
$4.80
$-0.75 (-13.51%)
Jan 5, 2026
Price History (1Y)
Analysis
Zura Bio Limited is a biotechnology company in the healthcare sector. With a market capitalization of $312.11M and approximately 30 employees, it operates at a relatively small scale compared to larger industry peers. The company's financial health is marked by significant losses, with net income totaling -$62,520,000 over the trailing twelve months. Additionally, it reported EBITDA of -$72,528,000 and free cash flow of -$28,158,376 during this period. The gross margin, operating margin, and profit margin are all at 0.0%, indicating no profitability. Returns on equity and assets are also negative, at -45.0% and -27.2%, respectively. Cash reserves total $139.02M. Valuation metrics for Zura Bio Limited include a forward P/E ratio of -6.49 and an EV/EBITDA ratio of -3.20. The price to book is 2.88, while the beta is 0.20.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Zura Bio Limited
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-independent inflammation, which has completed Phase 1/2 clinical studies; and Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor alpha chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways, which has completed Phase 1/1b clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
Visit website →Key Statistics
- Market Cap
- $312.11M
- P/E Ratio
- N/A
- 52-Week High
- $5.75
- 52-Week Low
- $0.97
- Avg Volume
- 626.90K
- Beta
- 0.20
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 30